Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Jason J. Luke, MD
Published: Wednesday, Dec 20, 2017



Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
SELECTED
LANGUAGE


Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x